Combination approvals for revumenib and ziftomenib in relapsed/refractory acute myeloid leukemia may arrive before frontline approvals, according to Eunice Wang, MD.

Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.

Adult T-cell lymphoma and leukemia may warrant upfront allogeneic transplant, according to Mary Jo Lechowicz, MD.

Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.

Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.

Azacitidine/venetoclax improving EFS over chemotherapy in fit patients with AML is an “important outcome,” according to Amir T. Fathi, MD.

Poster presentations at SOHO 2026 may inform practice across acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia.

The risk of infections with epcoritamab plus R2 appeared to level off after the first 4 cycles of therapy in the EPCORE FL-1 trial.